Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products

Elanco Animal Health Incorporated (NYSE: ELAN ) delivered strong financial performance for the second quarter of 2026, driven by robust demand across its Pet Health portfolio and expanding margins. The momentum led management to raise its full-year growth outlook. The pet health company reported adjusted earnings of 34 cents, beating the consensus of 27 cents. Zenrelia And Credelio Quattro Gain Traction Sales jumped 10% year-over-year on a reported basis (+8% on constant currency) to $1.368 billion, better than the consensus of $1.313 billion. Growth was headlined by the Pet Health segment, which increased 12% reported to $718 million. A 9% volume uptick in Pet Health was primarily driven by strong consumer demand for Zenrelia and Credelio Quattro. U.S. Pet Health’s 11% increase reflects strong growth inside the vet clinic, online and at retail, as well as in prescription and OT...